Kipp Weiskopf

8.1k citations

41 papers · 4.1k indexed · 3 hit papers · h-index 21

Impact in

Immunology top 0.5%
- Phagocytosis and Immune Regulation
- Immune cells in cancer
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Oncology top 2%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers

Papers in

Immunology 33
- Phagocytosis and Immune Regulation 25
- Immune cells in cancer 13
- Immune Cell Function and Interaction 11
- Complement system in diseases 5
- Immunotherapy and Immune Responses 4
Oncology 12
- CAR-T cell therapy research 6

Co-authors: Irving L. Weissman Stephen B. Willingham Aaron M. Ring Jens-Peter Volkmer Ravindra Majeti Nathaniel B. Fernhoff Humberto Contreras-Trujillo Mark P. Chao
Journals: Proceedings of the National Academy of Sciences (7 papers)Journal of Clinical Oncology (3 papers)OncoImmunology (3 papers)mAbs (2 papers)Science Translational Medicine (2 papers)
Partner nations: United States India Germany

In The Last Decade

Kipp Weiskopf

39 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy 2017 · 428 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Nature Immunology
2013 Proceedings of the National Academy of Sciences
2010 Science Translational Medicine

Peers

Countries citing papers authored by Kipp Weiskopf

Since Specialization

Citations

This map shows the geographic impact of Kipp Weiskopf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kipp Weiskopf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kipp Weiskopf more than expected).

Fields of papers citing papers by Kipp Weiskopf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kipp Weiskopf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kipp Weiskopf. The network helps show where Kipp Weiskopf may publish in the future.

Co-authors

The 25 scholars most cited alongside Kipp Weiskopf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kipp Weiskopf Line = papers co-authored together Kipp Weiskopf links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction Journal of Clinical Investigation ·Johs Br�ggemann, 闵小龙, Troy W. Whitfield, Asaf Maoz, Robert Ruscassie, K. Wissenbacfr, Dian Yang, Kendall G Kanakanui, Thennarasu S, Max-Philipp Stenner, Nicole Phan, George W. Bell, Aaron N. Hata, Kipp Weiskopf	2024	8
2	Cancer immunotherapy targeting the CD47/SIRPα axis European Journal of Cancer ·Kipp Weiskopf	2017	283
3	Delivery of monocyte lineage cells in a biomimetic scaffold enhances tissue repair JCI Insight ·Michael S. Hu, Graham G. Walmsley, Leandra A. Barnes, Kipp Weiskopf, Robert C. Rennert, Dominik Duscher, Michael Januszyk, Zeshaan N. Maan, Wan Xing Hong, Alexander T. M. Cheung, Tripp Leavitt, Clement D. Marshall, Ryan C. Ransom, Samir Malhotra, Alessandra L. Moore, Jayakumar Rajadas, H. Peter Lorenz, Irving L. Weissman, Geoffrey C. Gurtner, Michael T. Longaker	2017	57
4	Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy Nature Immunology ·Amira Barkal, Kipp Weiskopf, Kevin S. Kao, Sydney Gordon, Benyamin Rosental, Ying Ying Yiu, Benson M. George, Maxim Markovic, Nan Ring, Jonathan M. Tsai, Kelly M. McKenna, Po Y. Ho, Robin Z. Cheng, James Y. Chen, Layla J. Barkal, Aaron M. Ring, Irving L. Weissman, Roy L. Maute Hit paper breakdown →	2017	428
5	Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20 Cancer Immunology Research ·Kipp Weiskopf, Katie L. Anderson, Daisuke Ito, Peter J. Schnorr, Hirotaka Tomiyasu, Aaron M. Ring, Vincent C. W. Yeung, Jem Efe, Sarah Rue, David E. Lowery, Amira Barkal, Susan Prohaska, Kelly M. McKenna, Ingrid Cornax, Timothy D. O’Brien, Maeve O’Sullivan, Irving L. Weissman, Jaime F. Modiano	2016	43
6	SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells Clinical Cancer Research ·Emily Piccione, Silvia Juárez, Serena Tseng, Jie Liu, Melissa Stafford, Cyndhavi Narayanan, Lijuan Wang, Kipp Weiskopf, Ravindra Majeti	2016	41
7	Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts Cell Reports ·Lynette Tippett, Arum Han, Anita Lakatos, Debashis Sahoo, Stephanie J. Hachey, Kipp Weiskopf, Andrew H. Beck, Irving L. Weissman, Alexander D. Boiko	2016	60
8	Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors Proceedings of the National Academy of Sciences ·Geoffrey W. Krampitz, Benson M. George, Stephen B. Willingham, Jens-Peter Volkmer, Kipp Weiskopf, Nadine S. Jahchan, Aaron M. Newman, Debashis Sahoo, Allison Zemek, Rebecca L. Yanovsky, Julia Nguyen, Peter J. Schnorr, Paweł K. Mazur, Julien Sage, Teri A. Longacre, Brendan C. Visser, George A. Poultsides, Jeffrey A. Norton, Irving L. Weissman	2016	69
9	Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction Journal of Oncology Practice ·Kipp Weiskopf, Alexandro de Souza Brito, Thomas Lew, Jennifer L. Caswell‐Jin, David Ouyang, Gulshan Tanwar, Lawrence V. Hofmann, Joel W. Neal, Melinda L. Telli	2016	0
10	Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy Science Translational Medicine ·Akanksha Chhabra, Aaron M. Ring, Kipp Weiskopf, Peter J. Schnorr, Sydney Gordon, Alan Le, Hye‐Sook Kwon, Nan Ring, Jens Volkmer, Po Y. Ho, Serena Tseng, Irving L. Weissman, Judith A. Shizuru	2016	121
11	Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps Immunity ·Suman Mitra, Aaron M. Ring, Shoba Amarnath, Jamie B. Spangler, Peng Li, Lili Ju, Suzanne Fischer, Jangsuk Oh, Rosanne Spolski, Kipp Weiskopf, Holbrook E. Kohrt, Jason Foley, Sumati Rajagopalan, Eric O. Long, Daniel H. Fowler, Thomas A. Waldmann, K. Christopher García, Warren J. Leonard	2015	126
12	Macrophages are critical effectors of antibody therapies for cancer mAbs ·Kipp Weiskopf, Irving L. Weissman	2015	206
13	A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells mAbs ·Emily Piccione, Silvia Juárez, Jie Liu, Serena Tseng, Christine E. Ryan, Cyndhavi Narayanan, Lijuan Wang, Kipp Weiskopf, Ravindra Majeti	2015	119
14	“Velcro” Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein α (SIRPα) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis Journal of Biological Chemistry ·Chia Chi M. Ho, Nan Guo, Jonathan T. Sockolosky, Aaron M. Ring, Kipp Weiskopf, Engin Özkan, Yasuo Mori, Irving L. Weissman, K. Christopher García	2015	74
15	Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies Science ·Kipp Weiskopf, Aaron M. Ring, Chia Chi M. Ho, Jens-Peter Volkmer, Aron M. Levin, Anne Kathrin Volkmer, Engin Özkan, Nathaniel B. Fernhoff, Matt van de Rijn, Irving L. Weissman, K. Christopher García	2013	376
16	Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants OncoImmunology ·Kipp Weiskopf, Aaron M. Ring, Peter J. Schnorr, Jens-Peter Volkmer, Anne Kathrin Volkmer, Irving L. Weissman, K. Christopher García	2013	11
17	A Nonpeptidic Cathepsin S Activity-Based Probe for Noninvasive Optical Imaging of Tumor-Associated Macrophages Chemistry & Biology ·Martijn Verdoes, Laura E. Edgington‐Mitchell, Ferenc A. Scheeren, Melissa J. Leyva, Galia Blum, Kipp Weiskopf, Michael H. Bachmann, Jonathan A. Ellman, Matthew Bogyo	2012	96
18	Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma Proceedings of the National Academy of Sciences ·Badreddin Edris, Kipp Weiskopf, Anne Kathrin Volkmer, Jens-Peter Volkmer, Stephen B. Willingham, Humberto Contreras-Trujillo, Jie Liu, Ravindra Majeti, Robert B. West, Jonathan A. Fletcher, Andrew H. Beck, Irving L. Weissman, Matt van de Rijn	2012	211
19	Flipping the script on macrophages in leiomyosarcoma OncoImmunology ·Badreddin Edris, Kipp Weiskopf, Irving L. Weissman, Matt van de Rijn	2012	8
20	Asterless is a scaffold for the onset of centriole assembly Nature ·Nikola S. Dzhindzhev, 叶洪珍, Kipp Weiskopf, George Tzolovsky, Inês Cunha‐Ferreira, Maria Giovanna Riparbelli, Ana Rodrigues-Martins, Mónica Bettencourt‐Dias, Giuliano Callaini, David M. Glover	2010	232

About Kipp Weiskopf

Kipp Weiskopf is a scholar working on Immunology, Oncology, Gastroenterology, Hematology and Physiology, having authored 41 papers that have together received 4.1k indexed citations. Recurring topics across this work include Phagocytosis and Immune Regulation (25 papers), Immune cells in cancer (13 papers), Immune Cell Function and Interaction (11 papers), Erythrocyte Function and Pathophysiology (7 papers), CAR-T cell therapy research (6 papers), Complement system in diseases (5 papers), Pancreatic function and diabetes (5 papers) and Immunotherapy and Immune Responses (4 papers). The work is most often cited by research in Immunology (2.9k citations), Oncology (1.2k citations), Cell Biology (347 citations), Physiology (507 citations) and Molecular Biology (1.1k citations). Kipp Weiskopf has collaborated with scholars based in United States, India and Germany. Frequent co-authors include Irving L. Weissman, Stephen B. Willingham, Aaron M. Ring, Jens-Peter Volkmer, Ravindra Majeti, Nathaniel B. Fernhoff, Humberto Contreras-Trujillo, Mark P. Chao, Jens Volkmer and Matt van de Rijn. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology, OncoImmunology, mAbs and Science Translational Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact